Decreased β-isomerization of the C-terminal telopeptide of type I collagen α1 chain in Paget's disease of bone

Journal of Bone and Mineral Research

Volumn 12, Issue 9, 1997, Pages 1407-1415

  Garnero, Patrick ^a   Fledelius, Christian ^b   Gineyts, Evelyne ^a   Serre, Claire Marie ^a   Vignot, Emanuelle ^a   Delmas, Pierre D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1;

ADULT; AGED; ARTICLE; BONE DEFECT; BONE MATRIX; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; ISOMERISM; MALE; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIMARY HYPERPARATHYROIDISM; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; BIOLOGICAL MARKERS; BONE AND BONES; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; ISOMERISM; MALE; MIDDLE AGED; MODELS, CHEMICAL; OSTEITIS DEFORMANS; PEPTIDES;

EID: 0030763499     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1997.12.9.1407     Document Type: Article

References (22)

1. Delmas PD, Garnero P 1996 Utility of biochemical markers in osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.) Osteoporosis. Academic Press, San Diego, CA, U.S.A., pp. 1075-1085.
2. Eyre DR 1987 Collagen crosslinking amino-acids. Meth Enzymol 144:115-139.
3. Fujimoto D, Suzuki M, Uchiyama A, Miyamoto S, Inoue T 1983 Analysis of pyridinoline, a cross-linking compound of collagen fibres, in human urine. J Biochem 94:1133-1136.
4. Eyre DR, Ericsson L, Simon L, Krane S 1988 Identification of urinary peptides derived from cross-linking sites in bone collagen in Paget's disease. J Bone Miner Res S210.
5. Seyedin SM, Kung VT, Daniloff YN, Hesley RP, Gomez B, Nielsen LA, Rosen HN, Zuk RF 1993 Immunoassay for urinary pyridinoline: The new marker of bone resorption. J Bone Miner Res 8:635-641.
6. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ 1994 Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649.
7. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025.
8. Hanson DA, Weis MA, Bollen A-M, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 11:1251-1258.
9. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F 1993 Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 8:643-648.
10. Garnero P, Gineyts E, Riou J-P, Delmas PD 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785.
11. Garnero P, Shih W, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate therapy. J Clin Endocrinol Metab 79:1693-1700.
12. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1995 Applications of an enzyme immunoassay for a new marker of bone resorption (Crosslaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:564-568.
13. Fledelius C, Johnsen AH, Cloos P, Bonde M, Qvist P 1997 Characterization of urinary degradation products derived from type I collagen: Identification of a β-isomerized aspartyl residue within the C-telopeptide (α1) region. J Biol Chem 272:9755-9763.
14. Lowenson J, Clarke S 1988 Does the chemical instability of aspartyl and asparaginyl residues in proteins contribute to erythrocyte aging? Blood Cells 14:103-117.
15. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurker-Neely HA, Heinrikson RL, Ball MJ, Greenberg BD 1993 Structural alterations in the peptide backbone of β amyloid core protein may account for its deposition and stability in Alzheimer Disease. J Biol Chem 268: 3072-3083.
16. Bonde M, Fledelius C, Qvist P, Christiansen C 1996 Coated tube radioimmunoassay for C. telopeptides of type I collagen to assess bone resorption. Clin Chem 42:1639-1644.
17. Siris ES 1993 Paget's disease of bone. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of the Mineral Metabolism. Raven Press, New York, NY, U.S.A., pp. 375-384.
18. Meunier PJ, Coindre J, Edouard CM, Arlot ME 1980 Bone histomorphometry in Paget's disease: Quantitative and dynamic analysis of pagetic and non-pagetic bone tissue. Arth Rheum 23:1073-1234.
19. Meunier PJ, Saison C, Mathieu L, Chapuy MC, Delmas PD, Charhon S 1987 Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop 217:37-44.
20. Coutris G, Cayla J, Rondier J, Talbot J-N, Bonvarlet J-P, Milhaud G 1975 Analyse des perturbations des voies principales du métabolisme calcique dans la maladie de Paget: Effets de l'administration de calcitonine. Rev Rheum 42: 759-767.
21. Uebelhart D, Gineyts E, Chapuy M-C, Delmas PD 1990 Urinary excretion of pyridinium crosslinks: A new marker of bone resorption in metabolic bone disease. Bone Miner 8:87-89.
22. Geiger T, Clarke S 1987 Deamination, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. J Biol Chem 262:785-794.